Clinical Trials Directory

Trials / Completed

CompletedNCT00042250

IUdR/BUdR Cell Cycle Labelling

Cell Cycle Kinetics in Vivo in Patients With Hematologic Malignancies Studied by Iododeoxyuridine and Bromodeoxyuridine Labelling

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
28 (actual)
Sponsor
M.D. Anderson Cancer Center · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

To determine cell cycle parameters and changes after treatment, the labelling agent is given and a bone marrow aspiration is accomplished before treatment and after treatment for comparison. Participants must be undergoing concurrent therapy for hematologic malignancy.

Detailed description

Cell cycle parameters include LI, Ts, Tc, T dpot, changes in these parameters, and differences between normal and leukemic cells in patients with hematologic malignancy prior to and following treatment.

Conditions

Interventions

TypeNameDescription
DRUGChemotherapy for hematologic malignancy

Timeline

Start date
1992-05-01
Primary completion
2002-10-01
Completion
2002-10-01
First posted
2002-07-26
Last updated
2012-01-24

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT00042250. Inclusion in this directory is not an endorsement.